General Provisions - The purpose of the management system is to strengthen the management of shares held by the company's directors and senior management, and to clarify management procedures based on relevant laws and regulations [1][2] - Directors and senior management are prohibited from engaging in margin trading with the company's stock [2][5] Information Reporting Regulations - The company secretary is responsible for managing the identity and shareholding data of directors and senior management, and must report personal information to the Shenzhen Stock Exchange within specified timeframes [4][5] - Directors and senior management must ensure the accuracy and timeliness of the information submitted to the Shenzhen Stock Exchange [6] Trading Regulations - Directors and senior management must notify the company secretary in writing before trading the company's stock, and the securities department must verify compliance with disclosure and legal requirements [9][10] - A reduction plan must be reported to the board at least 15 trading days before any share transfer, detailing the number of shares, reasons, and methods for reduction [7][10] Prohibited Trading Periods - Directors and senior management are prohibited from transferring shares under certain conditions, such as within one year of the company's stock listing or within six months after leaving the company [12][13] - Trading is also restricted during specific periods, such as before the announcement of annual or quarterly reports [13] Penalties and Responsibilities - Violations of the trading regulations may result in administrative or criminal liability, and the company must cooperate with relevant authorities [26][27] - Shareholders holding more than 5% of the company's shares must comply with relevant regulations regarding share trading [27] Additional Provisions - The company board holds the interpretation rights of this management system, which takes effect upon approval by the board [29][30]

盈康生命科技股份有限公司 盈康生命科技股份有限公司 投资者关系管理制度 （2025 年 6 月） 第一章 总 则 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则： （一）合规性原则。公司投资者关系管理应当在依法履行信息披露义务的基 础上开展，符合法律、法规、规章及规范性文件、行业规范和自律规则、公司内 部规章制度，以及行业普遍遵守的道德规范和行为准则。 盈康生命科技股份有限公司 （二）平等性原则。公司开展投资者关系管理活动，应当平等对待所有投资 者，尤其为中小投资者参与活动创造机会、提供便利。 （三）主动性原则。公司应当主动开展投资者关系管理活动，听取投资者意 见建议，及时回应投资者诉求。 （四）诚实守信原则。公司在投资者关系管理活动中应当注重诚信、坚守底 线、规范运作、担当责任，营造健康良好的市场生态。 第四条 投资者关系管理的目的： （一）促进公司与投资者之间的良性关系，增 ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 媒体来访和投资者调研接待工作管理办法 （2025 年 6 月） 第一章 总则 第一条 为贯彻证券市场公开、公平、公正原则，规范盈康生命科技股份有限 公司（以下简称"公司"）对外接待行为，加强公司对外接待及与外界的交流和沟 通，提高公司投资者关系管理水平，根据《中华人民共和国公司法》 《中华人民共 和国证券法》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 2 号——创业板上市公司规范运作》等法律法规和规范性文件以及公司 章程的规定，结合公司实际，制定本办法。 第二条 本规定所述的投资者调研接待工作，是指公司通过接受投资者、媒体、 证券机构的调研、一对一沟通、一对多沟通、现场参观、分析师会议、路演和业 绩说明会、新闻采访等活动，增进资本市场对公司的了解和认同的工作。 第三条 本规定所称重大信息是指对公司股票及其衍生品种交易价格可能或 已经产生较大影响的信息，包括下列信息： （一）与公司业绩、利润分配等事项有关的信息，如财务业绩、盈利预测、 利润分配和资本公积金转增股本等； （二）与公司收购兼并、资产重组等事项有关的信息； （三）与公司股 ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 内幕信息知情人登记制度 （2025 年 6 月） 第一章 总则 第一条 为进一步规范盈康生命科技股份有限公司（以下简称"公司"）内幕 信息管理行为，加强内幕信息保密工作，维护公司信息披露的公平、公正、公开 原则，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易所创业板股票 上市规则》（以下简称"《创业板上市规则》"）、《深圳证券交易所上市公司 自律监管指引第 2 号——创业板上市公司规范运作》（以下简称"《创业板上市 公司规范运作》"）、《上市公司信息披露管理办法》以及《盈康生命科技股份 有限公司章程》(以下简称"《公司章程》")的有关规定，特制定本制度。 第二条 内幕信息的管理工作由董事会负责，董事长为主要责任人，董事会秘 书组织实施。证券部是公司信息披露管理、投资者关系管理、内幕信息登记备案 的日常办事机构，并负责公司内幕信息的监管工作。 第三条 未经董事会批准同意，在内幕消息依法披露前，公司任何部门和个人 或其他获取内幕消息的人不得公开或向外界透露、泄露、报道、传送有关公司内 ...

Core Points - The article outlines the establishment and operational guidelines of the Compensation and Assessment Committee of Yinkang Life Science Technology Co., Ltd. to enhance the governance structure and management of director and senior management compensation [1][3][4] Group 1: General Provisions - The Compensation and Assessment Committee is a specialized committee under the board of directors responsible for setting assessment standards and compensation policies for directors and senior management [1][3] - The committee consists of three directors, including two independent directors, and is chaired by an independent director [3][4] Group 2: Responsibilities and Authority - The committee's main responsibilities include formulating compensation plans based on management roles, reviewing performance evaluations, and supervising the execution of compensation policies [3][8] - The committee must submit compensation plans for directors to the board for approval and subsequently to the shareholders' meeting for ratification [4][5] Group 3: Decision-Making Procedures - The committee is required to prepare for decision-making by gathering relevant financial and operational data, including performance metrics and management responsibilities [5][6] - Performance evaluations for directors and senior management involve self-assessments and adherence to established performance standards [6][7] Group 4: Meeting Rules - The committee holds regular meetings at least once a year and can convene temporary meetings as needed, with specific notification requirements [6][7] - Decisions require the presence of at least two-thirds of the committee members, and voting is conducted by a show of hands or through written communication for temporary meetings [7][8] Group 5: Miscellaneous Provisions - The guidelines specify that all meetings must be documented, and members are bound by confidentiality regarding discussed matters [8][8] - The guidelines take effect upon approval by the board and are subject to relevant national laws and regulations [8]

General Overview - The company has established a system for accountability regarding significant errors in annual report disclosures to enhance the quality and transparency of its financial reporting [1][2]. Scope of the System - The accountability system applies to the company's board members, senior management, subsidiary heads, controlling shareholders, and other personnel involved in annual report disclosures [2]. Definition of Accountability - Accountability refers to the pursuit and handling of individuals responsible for significant errors in annual report disclosures that lead to economic losses or adverse social impacts [2][3]. Principles of Accountability - The system adheres to principles of factual accuracy, objectivity, fairness, proportionality of fault and responsibility, and equivalence of rights and responsibilities [2]. Reporting and Handling Errors - The company secretary is responsible for reporting significant errors in annual report disclosures to the board and proposing corrective actions for board approval [2]. Conditions for Accountability - Individuals may be held accountable for significant errors if they violate national laws, company regulations, or fail to follow established procedures, leading to adverse impacts [3]. Forms of Accountability - Possible forms of accountability include correction orders, public reprimands, job transfers, fines, compensation for losses, termination of employment, and other legally compliant measures [4]. Considerations in Accountability - When determining accountability, the company will consider the reasons for the error, its consequences, and the individual's position and responsibilities within the company [4]. Cooperation with Investigations - Individuals responsible for annual report disclosures are obligated to cooperate with regulatory bodies or the company during investigations, providing truthful statements and evidence [4]. Performance Evaluation - The outcomes of accountability for significant errors in annual report disclosures will be included in the annual performance evaluation metrics for relevant departments and personnel [4]. Compliance with Regulations - The system will be revised in accordance with any future changes in national laws or company regulations, ensuring compliance and timely updates [5].

Meeting Information - The company will hold its first extraordinary general meeting of shareholders for 2025 on July 4, 2025, at 14:30 [1] - Shareholders can participate in the meeting either in person or via online voting through the Shenzhen Stock Exchange systems [2][5] Voting Procedures - Shareholders registered by the close of trading on June 27, 2025, are entitled to attend and vote at the meeting [2][5] - Voting can be conducted through the Shenzhen Stock Exchange trading system or the internet voting system [6][9] Agenda Items - The meeting will discuss several proposals, including the election of three non-independent directors and the abolition of a specific resignation and dismissal system for directors and senior management [4][14] - Proposal 13 will utilize a cumulative voting system, allowing shareholders to allocate their votes among the candidates [5][10] Registration and Attendance - Shareholders must present identification and relevant documents for registration [6][8] - Proxy representation is allowed, and the proxy does not need to be a shareholder of the company [2][6] Contact Information - For inquiries, shareholders can contact Liu Zelin at the provided phone number, fax, or email [6][8]

第二条 内幕信息的管理工作由董事会负责，董事长为主要责任人，董事会秘 书组织实施。证券部是公司信息披露管理、投资者关系管理、内幕信息登记备案 的日常办事机构，并负责公司内幕信息的监管工作。 第三条 未经董事会批准同意，在内幕消息依法披露前，公司任何部门和个人 或其他获取内幕消息的人不得公开或向外界透露、泄露、报道、传送有关公司内 幕信息及信息披露的内容。对外报道、传送的文件、音像及光盘等涉及内幕信息 及信息披露的内容的资料，须经董事会的审核同意，方可对外报道、传送。任何 单位和个人不得非法要求信息披露义务人提供依法需要披露但尚未披露的信息。 第四条 公司董事、高级管理人员和公司各部门、子（分）公司都应做好内幕 信息的保密工作。 盈康生命科技股份有限公司 盈康生命科技股份有限公司 内幕信息知情人登记制度 （2025 年 6 月） 第一章 总则 第一条 为进一步规范盈康生命科技股份有限公司（以下简称"公司"）内幕 信息管理行为，加强内幕信息保密工作，维护公司信息披露的公平、公正、公开 原则，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《深圳证券交易 ...

盈康生命科技股份有限公司 投资者关系管理制度 （2025 年 6 月） 第一章 总 则 第一条 为了加强和规范盈康生命科技股份有限公司（以下简称"公司"）与 投资者及潜在投资者（以下合称"投资者"）之间的信息沟通，促进投资者对公 司的了解和认同，促使公司和投资者之间建立长期、稳定的良性关系，促进公司 诚信自律、规范运作，进一步完善公司法人治理结构，提升公司投资价值，实现 公司价值最大化和股东权益最大化，根据《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司投资者关系管理工作指引》《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等有关法律、法规、规章、规范性文件及《公司章程》的有关规 定，结合公司的实际情况，特制定本制度。 盈康生命科技股份有限公司 第二条 投资者关系管理是指公司通过便利股东权利行使、信息披露、互动 交流和诉求处理等工作，加强与投资者及潜在投资者之间的沟通，增进投资者对 公司的了解和认同，以提升公司治理水平和企业整体价值，实现尊重投资者、回 报投资者、保护投资者目的的相关活动。 第三条 投资者关系管理的基本原则： （一） ...

盈康生命科技股份有限公司 盈康生命科技股份有限公司 独立董事工作制度 （2025 年 6 月） 第一章 总 则 第一条 为进一步完善盈康生命科技股份有限公司（以下简称"公司"）治 理结构，强化对内部董事和经理层的约束和激励，保护公司股东尤其是中小投资 者的相关利益，促进公司规范运作，保证独立董事履行职责，根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《上市公司治理准则》《上市公司 独立董事管理办法》《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》（以下简称"《规范运作》"）及《盈康生命科技股份有限公司 章程》（以下简称"《公司章程》"）等相关规定，制定本制度。 第二条 公司独立董事是指不在公司担任除董事外的其他职务，并与公司及 其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其进 行独立客观判断关系的董事。 第三条 公司独立董事 3 名，聘任适当人员担任，其中至少包括一名会计专 业人士。会计专业人士指具有丰富的会计专业知识和经验，并至少符合下列条件 之一的人士：（1）具有会计、审计或者 ...